Radiopharmaceutical imaging developer Piramal Imaging will provide funding and support for the Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) clinical study.
Piramal's Neuraceq (florbetaben F-18) tracer will be one of three radiotracers used in the trial, which is designed to evaluate the effect of PET imaging of beta-amyloid deposits in the diagnosis of Alzheimer's disease in a certain patient population.
Neuraceq is indicated for PET imaging of the brain to estimate beta-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease and other causes of cognitive decline.
The IDEAS study is being led by the Alzheimer's Association and managed by the American College of Radiology (ACR) and American College of Radiology Imaging Network (ACRIN). The study will enroll a total of 18,488 eligible Medicare beneficiaries ages 65 and older at some 200 U.S. sites over the next two years.
